Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania: a diagnostic accuracy study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania : a diagnostic accuracy study. / SOLID collaborators.

I: The Lancet Infectious Diseases, Bind 24, Nr. 1, 01.2024, s. 98-106.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

SOLID collaborators 2024, 'Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania: a diagnostic accuracy study', The Lancet Infectious Diseases, bind 24, nr. 1, s. 98-106. https://doi.org/10.1016/S1473-3099(23)00378-X

APA

SOLID collaborators (2024). Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania: a diagnostic accuracy study. The Lancet Infectious Diseases, 24(1), 98-106. https://doi.org/10.1016/S1473-3099(23)00378-X

Vancouver

SOLID collaborators. Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania: a diagnostic accuracy study. The Lancet Infectious Diseases. 2024 jan.;24(1):98-106. https://doi.org/10.1016/S1473-3099(23)00378-X

Author

SOLID collaborators. / Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania : a diagnostic accuracy study. I: The Lancet Infectious Diseases. 2024 ; Bind 24, Nr. 1. s. 98-106.

Bibtex

@article{ed3e5c30ca074f929bf43decffef704d,
title = "Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania: a diagnostic accuracy study",
abstract = "BACKGROUND: Neurocysticercosis is a common cause of epilepsy in Taenia solium-endemic areas in sub-Saharan Africa but is often undiagnosed because of an absence of affordable diagnostic tools. This study evaluated the diagnostic accuracy of a T solium cysticercosis antibody-detecting lateral-flow point-of-care assay (TS POC test) for the neuroimaging-based diagnosis of neurocysticercosis.METHODS: Patients with epileptic seizures or severe progressive headache were recruited consecutively from three hospitals in southern Tanzania. All patients were tested with the TS POC test. All patients positive for cysticercosis on the TS POC test and every tenth patient who was negative for cysticercosis received a brain CT examination and underwent reference testing for T solium cysticercosis (ie, rT24H-EITB, LLGP-EITB, and antigen ELISA). The primary outcome of the study was the sensitivity of the TS POC test for the diagnosis of neurocysticercosis.FINDINGS: Of the 601 recruited participants, 102 (17%) tested positive for cysticercosis with the TS POC test. Overall, 48 (62%) of the 77 patients positive for cysticercosis and five (17%) of the 29 patients negative for cysticercosis on the TS POC test had CT-confirmed neurocysticercosis. The TS POC test yielded a sensitivity of 49% (uncertainty interval [UI] 41-58) for neurocysticercosis. Sensitivity was similar to that of the rT24H-EITB (44%, UI 37-51) and the antigen ELISA (50%, 43-56). For the subset of neurocysticercosis cases with at least one active (ie, vesicular) lesion, sensitivity was above 98% for the TS POC test, the rT24H-ETIB, and the antigen ELISA.INTERPRETATION: The TS POC test showed promising results for the diagnosis of neurocysticercosis in patients with vesicular lesions, which need to be confirmed in a larger study. This test could be considered to support policies on screening patients with suspected neurocysticercosis in clinical settings, which would allow appropriate referral for neuroimaging and early treatment.FUNDING: German Federal Ministry of Education and Research and the European & Developing Countries Clinical Trials Partnership.TRANSLATION: For the Swahili translation of the abstract see Supplementary Materials section.",
keywords = "Animals, Humans, Neurocysticercosis/diagnosis, Taenia solium, Tanzania, Cysticercosis/diagnosis, Epilepsy, Point-of-Care Testing",
author = "Dominik Stelzle and Makasi, {Charles E} and Veronika Schmidt and {Van Damme}, Inge and Chiara Trevisan and Charlotte Ruether and Agn{\`e}s Fleury and John Noh and Sukwan Handali and Pierre Dorny and Pascal Magnussen and Gideon Zulu and Mwape, {Kabemba E} and Emmanuel Bottieau and Sarah Gabri{\"e}l and Ngowi, {Bernard J} and Winkler, {Andrea S} and {SOLID collaborators}",
note = "Copyright {\textcopyright} 2024 Elsevier Ltd. All rights reserved.",
year = "2024",
month = jan,
doi = "10.1016/S1473-3099(23)00378-X",
language = "English",
volume = "24",
pages = "98--106",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "TheLancet Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Evaluation of a point-of-care test for the diagnosis of Taenia solium neurocysticercosis in rural southern Tanzania

T2 - a diagnostic accuracy study

AU - Stelzle, Dominik

AU - Makasi, Charles E

AU - Schmidt, Veronika

AU - Van Damme, Inge

AU - Trevisan, Chiara

AU - Ruether, Charlotte

AU - Fleury, Agnès

AU - Noh, John

AU - Handali, Sukwan

AU - Dorny, Pierre

AU - Magnussen, Pascal

AU - Zulu, Gideon

AU - Mwape, Kabemba E

AU - Bottieau, Emmanuel

AU - Gabriël, Sarah

AU - Ngowi, Bernard J

AU - Winkler, Andrea S

AU - SOLID collaborators

N1 - Copyright © 2024 Elsevier Ltd. All rights reserved.

PY - 2024/1

Y1 - 2024/1

N2 - BACKGROUND: Neurocysticercosis is a common cause of epilepsy in Taenia solium-endemic areas in sub-Saharan Africa but is often undiagnosed because of an absence of affordable diagnostic tools. This study evaluated the diagnostic accuracy of a T solium cysticercosis antibody-detecting lateral-flow point-of-care assay (TS POC test) for the neuroimaging-based diagnosis of neurocysticercosis.METHODS: Patients with epileptic seizures or severe progressive headache were recruited consecutively from three hospitals in southern Tanzania. All patients were tested with the TS POC test. All patients positive for cysticercosis on the TS POC test and every tenth patient who was negative for cysticercosis received a brain CT examination and underwent reference testing for T solium cysticercosis (ie, rT24H-EITB, LLGP-EITB, and antigen ELISA). The primary outcome of the study was the sensitivity of the TS POC test for the diagnosis of neurocysticercosis.FINDINGS: Of the 601 recruited participants, 102 (17%) tested positive for cysticercosis with the TS POC test. Overall, 48 (62%) of the 77 patients positive for cysticercosis and five (17%) of the 29 patients negative for cysticercosis on the TS POC test had CT-confirmed neurocysticercosis. The TS POC test yielded a sensitivity of 49% (uncertainty interval [UI] 41-58) for neurocysticercosis. Sensitivity was similar to that of the rT24H-EITB (44%, UI 37-51) and the antigen ELISA (50%, 43-56). For the subset of neurocysticercosis cases with at least one active (ie, vesicular) lesion, sensitivity was above 98% for the TS POC test, the rT24H-ETIB, and the antigen ELISA.INTERPRETATION: The TS POC test showed promising results for the diagnosis of neurocysticercosis in patients with vesicular lesions, which need to be confirmed in a larger study. This test could be considered to support policies on screening patients with suspected neurocysticercosis in clinical settings, which would allow appropriate referral for neuroimaging and early treatment.FUNDING: German Federal Ministry of Education and Research and the European & Developing Countries Clinical Trials Partnership.TRANSLATION: For the Swahili translation of the abstract see Supplementary Materials section.

AB - BACKGROUND: Neurocysticercosis is a common cause of epilepsy in Taenia solium-endemic areas in sub-Saharan Africa but is often undiagnosed because of an absence of affordable diagnostic tools. This study evaluated the diagnostic accuracy of a T solium cysticercosis antibody-detecting lateral-flow point-of-care assay (TS POC test) for the neuroimaging-based diagnosis of neurocysticercosis.METHODS: Patients with epileptic seizures or severe progressive headache were recruited consecutively from three hospitals in southern Tanzania. All patients were tested with the TS POC test. All patients positive for cysticercosis on the TS POC test and every tenth patient who was negative for cysticercosis received a brain CT examination and underwent reference testing for T solium cysticercosis (ie, rT24H-EITB, LLGP-EITB, and antigen ELISA). The primary outcome of the study was the sensitivity of the TS POC test for the diagnosis of neurocysticercosis.FINDINGS: Of the 601 recruited participants, 102 (17%) tested positive for cysticercosis with the TS POC test. Overall, 48 (62%) of the 77 patients positive for cysticercosis and five (17%) of the 29 patients negative for cysticercosis on the TS POC test had CT-confirmed neurocysticercosis. The TS POC test yielded a sensitivity of 49% (uncertainty interval [UI] 41-58) for neurocysticercosis. Sensitivity was similar to that of the rT24H-EITB (44%, UI 37-51) and the antigen ELISA (50%, 43-56). For the subset of neurocysticercosis cases with at least one active (ie, vesicular) lesion, sensitivity was above 98% for the TS POC test, the rT24H-ETIB, and the antigen ELISA.INTERPRETATION: The TS POC test showed promising results for the diagnosis of neurocysticercosis in patients with vesicular lesions, which need to be confirmed in a larger study. This test could be considered to support policies on screening patients with suspected neurocysticercosis in clinical settings, which would allow appropriate referral for neuroimaging and early treatment.FUNDING: German Federal Ministry of Education and Research and the European & Developing Countries Clinical Trials Partnership.TRANSLATION: For the Swahili translation of the abstract see Supplementary Materials section.

KW - Animals

KW - Humans

KW - Neurocysticercosis/diagnosis

KW - Taenia solium

KW - Tanzania

KW - Cysticercosis/diagnosis

KW - Epilepsy

KW - Point-of-Care Testing

U2 - 10.1016/S1473-3099(23)00378-X

DO - 10.1016/S1473-3099(23)00378-X

M3 - Journal article

C2 - 37660709

VL - 24

SP - 98

EP - 106

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 1

ER -

ID: 377365596